Yesterday, the FDA sent out a new round of warning letters to 15 firms that have been making disease claims about CBD goods. We commend the agency for its continuing vigilance against this illegal practice that threatens customer security and undermines self-assurance in the hemp business.
Even so, accompanying these announcements was new public guidance from the FDA that we think severely overstates the wellness dangers of hemp-derived CBD and that ignores a great deal of the scientific proof of CBD’s security, in distinct at dosage levels usually located in foods and dietary supplements. Additional, devoid of enough scrutiny or public input, the FDA tends to make a broad statement that it can’t conclude that CBD is typically recognized as protected (GRAS), undermining its status as a food ingredient.
Combined with the FDA’s continued delay in sharing its extended-promised timetable for regulatory action, yesterday’s announcements raise substantial issues for us the Roundtable. We will be discussing subsequent actions with our allies on Capitol Hill and will be sharing with you shortly a strategy for political action.